People with NAFLD often present as obese, with insulin resistance and/or type 2 diabetes (T2DM), dyslipidaemia, hypertriglyceridaemia, and hypertension, all of which are risk factors for cardiovascular disease1,2

Approximately one in five people with NAFLD have T2DM1,3

Over 90% of patients with severe obesity undergoing bariatric surgery have NAFLD1

Given that the prevalence of NAFLD is expected to rise significantly in the next decade due to increasing obesity,endocrinologists have a vital role to play in the assessment and management of affected individuals.

NAFLD risk factors

Information on at risk populations: people with type 2 diabetes mellitus (T2DM), obesity and metabolic syndrome.

Testing for NAFLD

Exploring tests carried out in primary care for individuals at high risk of NAFLD.

Diabetes and NAFLD

This page focuses on the prevalence of NAFLD in people with T2DM.

The burden of NAFLD and NASH in diabetes

Exploring the social and economic burden of NAFLD and NASH related to people with T2DM. 

NASH and obesity

Information on the prevalence of NAFLD in people with obesity. This page explores lifestyle factors, assessment and obesity and advanced fibrosis due to NASH.

Referral and diagnosis of NASH

Screening and referral algorithms and diagnostic testing for patients with suspected advanced fibrosis due to NASH. 

NASH and NAFLD toolkit

A collection of links to resources for healthcare professionals exploring prevention, screening tools, treatment guidelines and more. 

References

  1. Younossi Z, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol 2016;64:73-84.
  2. Kasturiratne A, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol 2013;28:142–7.
  3. Yamazaki H, et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes mellitus. Diabetes Care 2015;38:1673–9.

LID/IHQ/18-12//1048E DATE OF PREPARATION: March 2019